Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout has maintained an Overweight rating on CytomX Therapeutics (NASDAQ: CTMX) and increased the price target from $10 to $16. This adjustment reflects a positive outlook for the company's performance.